GlassScriptPhysician profile
Monique L Moseley
NPI 1336378280
$3,949.90
in general payments reported to CMS, 2019-2025
33 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $786 · 2023: $1,094 · 2024: $1,066 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $619.33 | 2023-2025 | Ingrezza, Ongentys |
| Bayer Healthcare Pharmaceuticals INC. | $574.20 | 2022-2025 | |
| Lilly USA, LLC | $444.12 | 2022-2024 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $271.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $207.59 | 2022-2025 | Eliquis |
| Sumitomo Pharma America, INC. | $163.82 | 2023-2025 | Gemtesa, Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $150.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $119.22 | 2022-2024 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $112.62 | 2023-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $111.44 | 2022-2024 | Verquvo, Capvaxive, Belsomra |
| Shield Therapeutics INC | $109.50 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.29 | 2022-2025 | Ofev |
| Daiichi Sankyo INC. | $96.07 | 2022-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $78.58 | 2022-2023 | Trintellix |
| Ardelyx, INC. | $75.84 | 2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.29 | 2023-2024 | Xarelto |
| Pfizer INC. | $65.38 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.92 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $64.06 | 2024-2025 | Rexulti |
| Abbvie INC. | $62.72 | 2023-2025 | |
| Amgen INC. | $61.15 | 2024 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $52.53 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $48.86 | 2024-2025 | Korlym |
| Dexcom, INC. | $48.16 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $48.15 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Organogenesis INC. | $21.92 | 2025 | Puraply Wound Matrix |
| Seqirus USA INC | $18.91 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Teleflex LLC | $18.13 | 2024 | Urolift |
| Amarin Pharma, INC. | $16.80 | 2022 | |
| Ucb, INC. | $15.25 | 2024 | Nayzilam |
| Ironwood Pharmaceuticals, INC | $14.01 | 2024 | |
| Esperion Therapeutics, INC. | $13.72 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Moseley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.